I think that stigma creates problems, for both patients and clinicians.
Not currently indicated for ASCVD risk reduction
However, despite the rather modest weight loss with the drug in this trial, these patients with preserved ejection fraction heart failure demonstrated clinically significant improvements in quality of life, measures of functional capacity, reductions in important biomarkers including NT proBNP and CRP, and numerically less likelihood of heart failure decompensation. In the published paper, the researchers hypothesize that the weight-loss-independent benefits of semaglutide in HFpEF may include direct effects on decongestion
The more we emotionally eat, the more our brain craves the dopamine hit, and the harder-wired the eating pattern becomes
Its a small but growing movement, NPR FDA clears spinal cord stimulator for home use, STAT Once a patients in custody, ICE can be at hospital bedsides but detainees have rights, KFF Health News Many poor countries where experimental drugs are tested fail to benefit after approval, analysis finds, STAT
DrugPatentWatchs databases track these thickets in detail, mapping which secondary patents are most likely to be asserted in litigation and which are most vulnerable to challenge
